Work

2002P Efficacy and biomarker analysis of neoadjuvant disitamab vedotin combined immunotherapy in patients with muscle-invasive bladder cancer: A multi-center real-world study

Year: 2024

Type: article

Study design: Observational Study

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2024.08.2088

Authors: L. Yan, J. Hu, J. Liu, J. Chen, X. Zu

Institutions: Central South University, Xiangya Hospital Central South University

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Bristol-Myers Squibb, Pfizer, Clovis Oncology, National Natural Science Foundation of China, China Postdoctoral Science Foundation, Eisai, LG Display, Astellas Pharma, Astellas Pharma Europe, Xiangya Hospital, Central South University

OpenAlex ID: W4402558652

FWCI:

Cites:

Cited by:

Related to: 10